Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $51.75.

Several equities analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Monday. JPMorgan Chase & Co. increased their price target on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 21.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VERA. Avoro Capital Advisors LLC acquired a new stake in shares of Vera Therapeutics during the first quarter worth $227,027,000. Kynam Capital Management LP grew its holdings in Vera Therapeutics by 23.5% during the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock worth $56,142,000 after acquiring an additional 694,286 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in Vera Therapeutics during the 1st quarter worth about $103,189,000. Vanguard Group Inc. raised its position in shares of Vera Therapeutics by 31.5% in the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after acquiring an additional 515,106 shares in the last quarter. Finally, Samlyn Capital LLC lifted its stake in shares of Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after purchasing an additional 586,410 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $40.02 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. Vera Therapeutics has a 52 week low of $9.24 and a 52 week high of $50.78. The stock has a market capitalization of $2.19 billion, a P/E ratio of -19.52 and a beta of 0.99. The stock has a fifty day moving average of $37.18 and a 200-day moving average of $39.08.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, sell-side analysts expect that Vera Therapeutics will post -2.59 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.